We understand that not all labs are alike. NGS applications and content need to be tailored for your lab's needs. A one-size-fits all approach just doesn't work, so we've developed a range of Oncomine NGS Assays to cover the spectrum of panel sizes and purposes. We listen and we create solutions for the way you work.
The Oncomine Precision Assay features carefully curated biomarker content spanning 50 genes based on relevant evidence.
Enhanced fusion detection provides broad coverage for the most prevalent isoforms, along with novel fusions. You have the option to profile DNA or RNA from FFPE tissue or plasma, giving you a wide range of utility.
All of this is provided with one-day turnaround time and a highly automated workflow on the Genexus System.
Comprehensive genomic profiling (CGP) of cancer types is bringing crucial insights to the advancement of oncology research.
In the past, the ability to provide such complex data has been compromised by technology limitations such as too high a sample type requirement, lower than optimal sequencing success rates, as well as the nonexistence of streamlined end-to-end workflow which would enable laboratories to generate the required amounts of such data.
The Oncomine Comprehensive Assay, a new version of the original assay with robust performance proven in large clinical oncology trials such as NCI MATCH, is a game changer.
1-day genomic profiling for myeloid malignancy research
With the Ion Torrent Oncomine Myeloid Assay Gx on the Ion Torrent Genexus System, you can get a comprehensive myeloid mutational profile from a single next-generation sequencing (NGS) run and results in just one day. A highly integrated workflow lets you go from specimen to report with only 10 minutes of hands-on time and two user touch points*. It’s never been easier to implement myeloid NGS testing in your lab.
A portfolio of research assays for both myeloid and lymphoid malignancies.
Hematological disorders are complex, heterogeneous diseases with many oncogenic drivers and subtypes. Acute forms of hematological malignancies are very aggressive and can proliferate rapidly. Getting fast, accurate, and meaningful insights is essential in helping to advance our understanding of these disorders.
Explore our growing portfolio of Oncomine hemato-oncology research assays. Whether you're interested in the assessment of myeloid or lymphoid malignancy samples, we provide the comprehensive suite of tools you need to simplify and expedite your path to answers.
Tumor Mutation Burden and other standard biomarkers from a single sample.
Tumor mutation burden (TMB) is an emerging biomarker that is rapidly gaining traction within the immuno-oncology field. Recent clinical trials have demonstrated that patients with higher TMB are more likely to respond to checkpoint inhibitor therapies, so it will likely become a part of routine clinical biomarker testing in the near future. Studies have shown that NGS is the best technique for detecting TMB. The Oncomine Tumor Mutation Load Assay is the only NGS solution available for use in clinical research laboratories that delivers a TMB assessment in one test workflow with other biomarkers.
Watch a short video of key opinion leaders talking about their experience with the test and assessing tumor mutation burden in ~2.5 days.
End-to-end solutions for liquid biopsy cancer research.
Whether you’re looking at multiple targets or just a few, our NGS solutions combine the power of Ion Torrent technology with cfDNA assays, advanced rare cell isolation, manual or automated cell-free DNA extraction, and digital PCR tools. Together, these solutions enable you to retrospectively assess cancer research samples throughout all stages.
For a complete listing of all available Oncomine assays, please visit Thermofisher.com. Find assays for a range of applications: